Drugs / CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07689058 | Jun 2026 → Dec 2027 expected | plasma cell myeloma | Dr. Zaineb Akram | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07689058 ↗ |
| Action | Deplete | “The Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a groundbreaking advancement in the field of immunotherapy, specifically designed to harness the patient's own...” NCT07689058 ↗ |
| Modality | Cell therapy | “engineered CAR T-cell therapy” NCT07689058 ↗ |